

Date Docketed 10-3-04Response Date 11-25-04

## UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
OCT - 3 2006

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

U.S. APPLICATION NUMBER:

10/368,233

NAME/NAMED APPLICANT:

Terrance L. Geiger

ATTY. DOCKET NO.:

SI-03-0016A

INTERNATIONAL APPLICATION NO.:

PCT/US04/25930

U.S. FILING DATE:

08/11/2004

PRIORITY DATE:

08/20/2003

28258  
 ST. JUDE CHILDREN'S RESEARCH HOSPITAL  
 OFFICE OF TECHNOLOGY LICENSING  
 332 N. LAUDERDALE  
 MEMPHIS, TN 38106

CONFIRMATION NO. 8594

371 FORMALITIES LETTER

'0C00000020549899'

Date Mailed: 09/26/2006

### NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- » This application clearly fails to comply with the requirements of 37 CFR 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 60 FR 18230 (May 1, 1995), and 1114 OG 29 (May 15, 1995). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- » A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

between the hours of 8 a.m. and 12 midnight, Monday through Friday, ET.

- Send e-mail correspondence for Patent Software Program Help to [abell@uspto.gov](mailto:abell@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.3).

A copy of this notice MUST be returned with the response.

TAMALA D HOLLAND

Telephone: (703) 305-9100 ext 203

**PART I - ATTORNEY/APPLICANT COPY**

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. EXCETN NO.
10/568,233	PCT/US2003/002300	SI-03-0016A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Terrence L. Geiger : Art Unit: To be Assigned

Serial No. 10/568,235 Examiner: To be Assigned

Filed: August 11, 2004 Atty Docket: SJ-03-0016A

(National Phase entry on  
February 14, 2006)

For: Chimeric Receptors with  
Disrupted Dileucine Motifs

**RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

Sir:

In response to the referenced notification dated September 25, 2006 and in accordance with 37 C.F.R. §1.821(e), Applicants hereby state that the computer readable form of the sequence listing for the present application is to be identical with the computer readable form of the sequence listing for U.S. Provisional Appln. No. 60/496,449 filed August 20, 2003, for which the

**Statement of Identity in accordance with 37 C.F.R. § 1.821(c):**

James Scott Elmer, undersigned attorney of record, hereby states that the content of the five page paper copy of the sequence listing included as part of the national phase entry submission for the present application on February 14, 2006 in accordance with 37 C.F.R. § 1.821(c), and the computer readable copy of the sequence listing originally submitted for U.S. Provisional Appln. No. 60/496,449 and adopted as the computer readable copy of the sequence listing for the present application in accordance with 37 CFR § 1.821(e), are the same.

Having complied with the referenced notification with respect to the requirement for a paper and computer readable copy of the sequence listing and a statement of identity in accordance with 37 C.F.R. §§ 1.821-1.825, Applicants respectfully submit that the present application is now in condition for examination. No fee is believed to be required for consideration of this submission. If applicants are incorrect and a fee is required the Commissioner is hereby authorized to charge such fee to Deposit Account No. 501968.

Respectfully submitted,



James Scott Elmer  
Attorney for Applicant  
Registration No. 36,129

St. Jude Children's Research Hospital  
332 North Lauderdale  
Memphis, TN 38105-2794  
Telephone: 901-495-2756

Date: October 6, 2006